CompletedPhase 4

Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules

Czechia206 participantsStarted 2012-03-08

Plain-language summary

The aim of this study is to investigate the immunogenicity response in adults up to 10 years after one booster dose. Data collected from this study will allow for greater information to prescribers who administer TBE vaccine, so that they can appropriately time the administration of booster vaccinations to individuals who received different vaccination schedules and who live in tick borne encephalitis endemic regions.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects who have completed prior study - V48P7E1. Exclusion Criteria: * Subjects whose antibody responses to booster vaccine received in the parent study fell below protective levels, subjects who have been exposed to TBE or flavivirus vaccine, subjects with immunosuppression.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Percentage of Subjects With Detectable TBE Antibody Titers Greater Than or Equal to (≥) 2

Timeframe: At Year 6

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2

Timeframe: At Year 7

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2

Timeframe: At Year 8

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2

Timeframe: At Year 9

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2

Timeframe: At Year 10

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 10

Timeframe: At Year 6

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 10

Timeframe: At Year 7

Trial details

NCT IDNCT01562444

SponsorGlaxoSmithKline

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2016-09-30

Results submitted2017-09-27

View on ClinicalTrials.gov More Tick Borne Encephalitis trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Percentage of Subjects With Detectable TBE Antibody Titers Greater Than or Equal to (≥) 2

Timeframe: At Year 6

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2

Timeframe: At Year 7

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2

Timeframe: At Year 8

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2

Timeframe: At Year 9

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 2

Timeframe: At Year 10

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 10

Timeframe: At Year 6

Percentage of Subjects With Detectable TBE Antibody Titers ≥ 10

Timeframe: At Year 7